Kyowa Kirin Co Ltd

Common Name
Kyowa Kirin
Country
Japan
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
5,669
Ticker
4151
Exchange
TOKYO STOCK EXCHANGE
Description
Kyowa Kirin Co., Ltd. is a prominent pharmaceutical company based in Japan, specializing in the research, development, and marketing of pharmaceuticals, biotechnology products, and medical devices. It...

Kyowa Kirin's Financial Statements Preview

Below are the financial statements of Kyowa Kirin, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.

Interested in getting early access to our real-time standardized financial datafeed?
Learn More
All figures in billions of JPY
2024 2024-01-01 - 2024-12-31
2023
Revenue
495.56a
442.23a
Cost of sales
-132.61a
-111.21a
Gross profit
362.95a
331.03a
Selling, general and administrative expenses
-167.54a
-163.08a
Research and development expenses
-103.54a
-72.11a
Share of profit (loss) of investments accounted for using equity method
3.54a
0.94a
Other income
13.1a
16.79a
Other expenses
-19.29a
-21.01a
Finance income
1.77a
4.87a
Finance costs
-7.54a
-0.19a
Profit before tax
83.45a
97.25a
Income tax expense
-23.58a
-16.06a
Profit
59.87a
81.19a
Profit attributable to
Owners of parent
59.87a
81.19a
Download Data

Verified Sources Behind Kyowa Kirin’s Financial Fundamentals Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Kyowa Kirin’s data sources below and access millions more through our Disclosure Search.

a. Kyowa Kirin's Financial Report 2024
a. Kyowa Kirin's Financial Report 2024
Real-Time & Standardized Financials

Access Standardized Financial Statements within Minutes of Disclosure

Tracenable is building real-time standardized financial datafeeds and APIs covering global equities. Unlike limited and inconsistent XBRL parsing, our approach aims to deliver clean, comparable, and fully traceable data seconds after publication.

Could this solution support your investment or analytical workflows?